Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Colorectal Neoplasms 653Pancreatic Neoplasms 394Carcinoma, Hepatocellular 311Stomach Neoplasms 255Rectal Neoplasms 184Colonic Neoplasms 183Esophageal Neoplasms 174Carcinoma, Non-Small-Cell Lung 171Breast Neoplasms 152Neoplasms 135Neoplasm Metastasis 133Ovarian Neoplasms 124Cholangiocarcinoma 112Lung Neoplasms 110Liver Neoplasms 109Gastrointestinal Neoplasms 101Melanoma 88Biliary Tract Neoplasms 77Prostatic Neoplasms 76Endometrial Neoplasms 74Esophageal Squamous Cell Carcinoma 68Carcinoma, Renal Cell 57Sarcoma 56Squamous Cell Carcinoma of Head and Neck 54Uterine Cervical Neoplasms 51Head and Neck Neoplasms 47Adenocarcinoma Of Esophagus 47Urinary Bladder Neoplasms 42Triple Negative Breast Neoplasms 40Anus Neoplasms 36

Interventions

Paroxetine 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lethal Congenital Contracture Syndrome 2 × Gastrointestinal × 90 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡